Today's Closing Update

U.S.Stocks slipped on Tuesday as the latest batch of earnings from companies such as Pfizer and Tapestry disappointed investors already concerned about rising costs and protectionist policies.

 

European Stocks inched higher, with U.K. equities driving the market action as most of the region’s markets were closed for May Day.

 

UK manufacturing activity expanded at the slowest pace in 17 months in April, survey data from IHS Markit showed Tuesday. The Markit/Chartered Institute of Procurement & Supply factory Purchasing Managers’ Index fell to 53.9 in April from 54.9 in March. The score was forecast to fall slightly to 54.8. Nonetheless, the indicator signaled expansion in each of the past 21 months.

 

BP held out the prospect of a first dividend increase since 2014 on Tuesday, after first-quarter profits beat forecasts thanks to rising oil and gas prices and production. Chief Financial Officer Brian Gilvary said the London-listed company might consider raising the dividend later this year if oil prices remain near current levels and debt declines.

 

John McFarlane said he is not about to quit as chairman of Barclays, adding that most shareholders backed Jes Staley to remain as the British bank’s chief executive following a misconduct inquiry. Barclays has faced uncertainty over its leadership, mainly due to regulatory scrutiny of Staley’s treatment of a whistleblower and concerns among some investors about its investment bank-focused strategy.

 

Britain’s media secretary Matt Hancock will give his verdict on Rupert Murdoch’s 18-month pursuit of Sky by June 13, potentially paving the way for Murdoch’s Fox to take on Comcast in the battle for the British TV group. Twenty-First Century Fox agreed a deal to buy the 61% of Sky it did not already own in December 2016 but the takeover has been repeatedly held up by politicians and regulators who fear it will give Murdoch too much influence in Britain.

 

Pfizer Inc racked up its biggest miss on sales in a year in the first quarter, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz. Pfizer shares, which have struggled to benefit from the surge in stock market prices since Donald Trump’s election in 2016, dipped just over 1% in response to the results.

 

National Grid said it had agreed to sell its remaining 25% interest in UK natural gas distributor Cadent Gas to the Quadgas Investments consortium for around £1.2bn. The company said it had an option to complete the sale any time between 1 March 2019 and 31 October 2019, subject to at least six months’ notice and meeting customary regulatory conditions.

 

WPP said it has taken over full ownership of three joint venture assets in south-east Asia and Taiwan. WPP has taken over its subsidiary Young & Rubicam’s joint venture operations in Malaysia, Singapore, Thailand, and Vietnam. It has also done the same for its subsidiary Wunderman in Thailand and Taiwan.

 

Oil Prices slid as the dollar remained near a four-month high, but worries that U.S. President Donald Trump will pull out of the Iran nuclear deal underpinned the market.

 

Gold Prices fell to a six-week low today as the dollar firmed near 3-1/2-month highs, with investors awaiting direction on US monetary policy from the US Federal Reserve.

Market Close

UK 100 7,520.4 +11.1 +0.2%
UK 250 20,348.3 +63.3 +0.3%
GER 30 12,612.11
FRA 40 5,520.5 +37.3 +0.7%
U.S. 30 23,883.85 -279.30 -1.2%
U.S. 500 2,632.1 -15.9 -0.6%
OIL (BRENT) 73.38 -1.31 -1.8%
GOLD 1,304.36 -11.03 -0.8%

UK Risers & Fallers

Just Eat 805.4 +31.6 +4.1%
Bunzl 2179 +68 +3.2%
Virgin Money 296.55 +18 +6.5%
British American Tobacco 3900 -99 -2.5%
Kingfisher 296.3 -7.5 -2.5%
Centamin 149.825 -7.15 -4.6%

Reported Economic Data

9.30am: U.K. Manufacturing PMI 55.1 54.8 53.9
9.30am: U.K. Net Lending to Individuals m/m 5.4bn 4.9bn 4.2bn
3.00pm: U.S. ISM Manufacturing PMI 59.3 58.4 57.3

Sources:

https://uk.reuters.com/article/us-bp-results/bp-flags-possible-dividend-boost-as-profits-surge-idUKKBN1I22WI

 

https://uk.reuters.com/article/uk-barclays-agm-chairman/barclays-chairman-insists-not-going-yet-shareholders-back-ceo-idUKKBN1I237Y?il=0

 

https://uk.reuters.com/article/uk-pfizer-results/pfizer-sales-miss-as-breast-cancer-drug-disappoints-idUKKBN1I23EB?il=0

 

http://www.londonstockexchange.com/exchange/news/alliance-news/detail/1525164995794593200.html

 

http://www.londonstockexchange.com/exchange/news/alliance-news/detail/1525164792014588300.html

 

http://www.londonstockexchange.com/exchange/news/alliance-news/detail/1525181906625232600.html

Subscribe to our Award-winning Newsletter

We provide daily market data in the form of our award-winning newsletter, The Morning Call and The Market Close.
You can subscribe to this information at any time to help you make the most of your investment.

Quick Sign-up

Recommendations: Collins Sarri Statham Investments Ltd (CSS) does not in any of its publications take into account any particular recipient's investment objectives, financial situation, and specific needs and demands. Therefore, all CSS publications are, unless otherwise specifically stated, intended for informational and/or marketing purposes only.CSS shall not be responsible for any loss arising from any investment based on a perceived recommendation.

No publication (including recommendations) shall be construed as a representation or warranty that the recipient will profit, nor avoid sustaining losses, from trading in accordance with a trading strategy set forth in a publication.

Risk Warning: Trading in the products and services offered by Collins Sarri Statham Investments Ltd (CSS) may, result in losses as well as profits as the value of investments may go down as well as up. You may not get back the full amount you have invested.

Any reference to past performance should not be viewed as an indication of any future performance.

Investments held in overseas markets are subject to the effects of changes in exchange rates which will impact on the value of the underlying investment.

Investments made in AIM and penny shares carry an increased risk due to the difficulty in creating a market in these shares. There may be a substantial difference in the buy and sell price.

Leveraged products such as Contracts for Difference (CFDs), derivatives, commodities & Foreign Exchange (FX), carry a higher risk to your capital. They can lose their value rapidly and you may lose substantially more than your initial investment.

Speculative trading is not suitable for all investors: The information contained herein is based on materials and sources that we believe to be reliable however we make no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Please note that the figures shown may, in some instances, be rounded to the nearest penny. Prices can move sharply from those quoted in this document. Current prices can be verified by calling one of our brokers. CSS is under no obligation to update the information contained herein. Neither CSS, nor its affiliates, nor its employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from the use of this document.

Get Started with CSS

Open an Account

Subscribe to our award winning daily newsletter

Voted "Best Market Newsletter" in 2012, 2014, 2015 and 2017 by the City of London Wealth Management Awards

Subscribe to our newsletter (Popup)

By signing up to our free email, you are consenting to receive these promotions. The newsletter is sent up to three times per day during the week and up to once per day over the weekend and is directed at UK residents. The newsletter contains company news, market movements, CSS research and promotions and breaking economic news. Occasionally our newsletter will contain advertisements from trusted partners. However, we will never give, sell or rent your email address to any other companies. If you want to stop receiving our free emails you can unsubscribe at any time by clicking on the link at the bottom of each email. You can read our privacy policy here.

Sending
No, thank you I am already subscribed